BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 16203265)

  • 1. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].
    Solassol J; Marin P; Maudelonde T; Mangé A
    Bull Cancer; 2005 Sep; 92(9):763-8. PubMed ID: 16203265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical proteomics and mass spectrometry profiling for cancer detection.
    Solassol J; Jacot W; Lhermitte L; Boulle N; Maudelonde T; Mangé A
    Expert Rev Proteomics; 2006 Jun; 3(3):311-20. PubMed ID: 16771703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
    Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
    BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
    Liu XP; Shen J; Li ZF; Yan L; Gu J
    Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical proteomics in breast cancer: a review.
    Gast MC; Schellens JH; Beijnen JH
    Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
    Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
    Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical proteomics: towards early detection of cancers].
    Solassol J; Boulle N; Maudelonde T; Mangé A
    Med Sci (Paris); 2005; 21(8-9):722-9. PubMed ID: 16115457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry].
    Zhang GQ; Du J; Pang D
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):204-7. PubMed ID: 16875606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
    Geng X; Wang F; Li YG; Zhu GP; Zhang WM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
    Engwegen JY; Gast MC; Schellens JH; Beijnen JH
    Trends Pharmacol Sci; 2006 May; 27(5):251-9. PubMed ID: 16600386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
    O'Gorman D; Howard JC; Varallo VM; Cadieux P; Bowley E; McLean K; Pak BJ; Gan BS
    Clin Invest Med; 2006 Jun; 29(3):136-45. PubMed ID: 17058431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
    Ricolleau G; Charbonnel C; Lodé L; Loussouarn D; Joalland MP; Bogumil R; Jourdain S; Minvielle S; Campone M; Déporte-Fety R; Campion L; Jézéquel P
    Proteomics; 2006 Mar; 6(6):1963-75. PubMed ID: 16470659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
    Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SELDI-TOF serum proteomics and breast cancer: which perspective?
    Garrisi VM; Abbate I; Quaranta M; Mangia A; Tommasi S; Paradiso A
    Expert Rev Proteomics; 2008 Dec; 5(6):779-85. PubMed ID: 19086858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
    Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proteomics and breast cancer].
    Mathelin C; Tomasetto C; Cromer A; Rio MC
    Gynecol Obstet Fertil; 2006 Dec; 34(12):1161-9. PubMed ID: 17123853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging: a review.
    Bakry R; Rainer M; Huck CW; Bonn GK
    Anal Chim Acta; 2011 Mar; 690(1):26-34. PubMed ID: 21414433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SELDI-TOF serum proteomics and colorectal cancer: a current overview.
    Gemoll T; Roblick UJ; Auer G; Jörnvall H; Habermann JK
    Arch Physiol Biochem; 2010; 116(4-5):188-96. PubMed ID: 20615064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].
    Gonçalves A; Bertucci F; Birnbaum D; Borg JP
    Med Sci (Paris); 2007 Mar; 23 Spec No 1():23-6. PubMed ID: 17669349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.